Denosumab versus Bisphosphonates for Reducing Fractures in Postmenopausal Women with Osteoporosis: A Meta-Analysis

References

1. 1.↵
   1. Looker AC,
   2. Frenk SM

   . Percentage of adults aged 65 and over with osteoporosis or low bone mass at the femur neck or lumbar spine: United States, 2005–2010 [Internet]; 2015. Available from: https://www.cdc.gov/nchs/data/hestat/osteoporsis/osteoporosis2005_2010.htm.
2. 2.↵
   1. Hughes DE,
   2. Mian M,
   3. Guilland-Cumming DF,
   4. Russell RG

   . The cellular mechanism of action of bisphosphonates. Drugs Exp Clin Res 1991;17:109–14.

   OpenUrlPubMed
3. 3.↵
   Lexicomp. [Internet]. Denosumab; 2020. Available from: http://online.lexi.com/. Accessed April 27, 2020.
4. 4.↵
   1. Hanley DA,
   2. Adachi JD,
   3. Bell A,
   4. Brown V

   . Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract 2012;66:1139–46.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Tu KN,
   2. Lie JD,
   3. Wan CKV,
   4. et al

   . Osteoporosis: a review of treatment options. P T 2018;43:92–104.

   OpenUrlPubMed
6. 6.↵
   1. Burke LA,
   2. Ryan AM

   . The complex relationship between cost and quality in US health care. AMA J Ethics 2014;16:124–30.

   OpenUrl
7. 7.↵
   1. Cummings SR,
   2. Black DM,
   3. Nevitt MC,
   4. et al

   . Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72–5.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Marshall D,
   2. Johnell O,
   3. Wedel H

   . Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254–9.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Liberati A,
   2. Altman DG,
   3. Tetzlaff J,
   4. et al

   . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65–94.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Vordemvenne T,
    2. Wähnert D,
    3. Klingebiel S,
    4. et al

    . Differentiation of traumatic osteoporotic and non-osteoporotic vertebral AO A3 fractures by analyzing the posterior edge morphology—a retrospective feasibility study. J Clin Med 2020;9:3910.

    OpenUrl
11. 11.↵
    1. Higgins JPT,
    2. Altman DG,
    3. Gotzsche PC

    , Cochrane Statistical Methods Groupet al. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ 2011;343:d5928.

    OpenUrlFREE Full Text
12. 12.↵
    1. Miller PD,
    2. Bolognese MA,
    3. Lewiecki EM,
    4. et al

    . Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008;43:222–9.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Brown JP,
    2. Prince RL,
    3. Deal C,
    4. et al

    . Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24:153–61.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Kendler DL,
    2. Roux C,
    3. Benhamou CL,
    4. et al

    . Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010;25:72–81.

    OpenUrlPubMed
15. 15.↵
    1. Freemantle N,
    2. Satram-Hoang S,
    3. Tang E-T

    , on behalf of the DAPS Investigators, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 2012;23:317–26.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Recknor C,
    2. Czerwinski E,
    3. Bone HG,
    4. et al

    . Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy. Obstetrics Gynecology 2013;121:1291–9.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Roux C,
    2. Hofbauer L,
    3. Ho P,
    4. et al

    . Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 2014;58:48–54.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Miller PD,
    2. Pannacciulli N,
    3. Brown JP,
    4. et al

    . Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinology Metabolism 2016;101:3163–70.

    OpenUrl
19. 19.↵
    1. Riaz H,
    2. Raza S,
    3. Khan MS,
    4. Riaz IB,
    5. Krasuski R

    . Impact of funding source on clinical trial results including cardiovascular outcomes trials. Am J Cardiol 2015;116:1944–7.

    OpenUrlPubMed
20. 20.↵
    1. Bouxsein ML,
    2. Eastell R,
    3. Lui L-Y

    , FNIH Bone Quality Project, et al. Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res 2019;34:632–42.

    OpenUrlCrossRef
21. 21.↵
    1. Wu J,
    2. Zhang Q,
    3. Yan G,
    4. Jin X

    . Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis. J Orthop Surg Res 2018;13:194.

    OpenUrl
22. 22.↵
    1. Beaudoin C,
    2. Jean S,
    3. Bessette L,
    4. Ste-Marie L-G,
    5. Moore L,
    6. Brown JP

    . Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporos Int 2016;27:2835–44.

    OpenUrl
23. 23.↵
    1. Lin T,
    2. Wang C,
    3. Cai XZ,
    4. et al

    . Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. Int J Clin Pract 2012;66:399–408.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Jackson RD,
    2. LaCroix AZ,
    3. Gass M,
    4. et al

    . Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669–83. Erratum in: N Engl J Med. 2006;354(10):1102.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Prasad V,
    2. Vandross A,
    3. Toomey C,
    4. et al

    . A decade of reversal: an analysis of 146 contraindicated medical practices. Mayo Clin Proc 2013;88:790–8.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Morizio P,
    2. Burkhart JI,
    3. Ozawa S

    . Denosumab: a unique perspective on adherence and cost-effectiveness compared with oral bisphosphonates in osteoporosis patients. Ann Pharmacother 2018;52:1031–41.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Ozaras N,
    2. Rezvani A

    . Diffuse skeletal pain after administration of alendronate. Indian J Pharmacol 2010;42:245–6.

    OpenUrlPubMed
28. 28.↵
    1. Liberman UA,
    2. Weiss SR,
    3. Bröll J,
    4. et al

    . Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437–44.

    OpenUrlCrossRefPubMedWeb of Science
29. 29.↵
    Bone Health & Osteoporosis Foundation [Internet]. Side effects of bisphosphonates (alendronate, ibandronate, risedronate and zoledronic acid); 2022. Available from: https://www.bonehealthandosteoporosis.org/patients/treatment/medicationadherence/side-effects-of-bisphosphonates-alendronate-ibandronate-risedronate-and-zoledronic-acid/. Accessed August 18, 2022.
30. 30.↵
    1. Hess LM,
    2. Jeter JM,
    3. Benham-Hutchins M,
    4. Alberts DS

    . Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 2008;121:475–83.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Yarom N,
    2. Shapiro CL,
    3. Peterson DE,
    4. et al

    . Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. J Clin Oncol 2019;37:2270–90.

    OpenUrl
32. 32.↵
    Bone Health & Osteoporosis Foundation [Internet]. Denosumab (Prolia); 2022. Available from: https://www.bonehealthandosteoporosis.org/patients/treatment/medicationadherence/denosumab-prolia/. Accessed August 18, 2022.
33. 33.↵
    1. Boquete-Castro A,
    2. Gómez-Moreno G,
    3. Calvo-Guirado JL,
    4. Aguilar-Salvatierra A,
    5. Delgado-Ruiz RA

    . Denosumab and osteonecrosis of the jaw: a systematic analysis of events reported in clinical trials. Clin Oral Implants Res 2016;27:367–75.

    OpenUrl
34. 34.↵
    1. Villa JC,
    2. Gianakos A,
    3. Lane JM

    . Bisphosphonate treatment in osteoporosis: optimal duration of therapy and the incorporation of a drug holiday. HSS J 2016;12:66–73.

    OpenUrl
35. 35.↵
    1. Gonzalez-Rodriguez E,
    2. Aubry-Rozier B,
    3. Stoll D,
    4. Zaman K,
    5. Lamy O

    . Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors. Breast Cancer Res Treat 2020;179:153–9.

    OpenUrl
36. 36.↵
    American Society for Bone and Mineral Research [Internet]. Joint guidance on osteoporosis management in the era of COVID-19 from the ASBMR, AACE, Endocrine Society, ECTS & NOF; 2022. Available from: https://www.asbmr.org/about/statement-detail/joint-guidance-on-osteoporosis-management-covid-19. Accessed August 18, 2022.